

Dr. Vinay Chopra  
MD (Pathology & Microbiology)  
Chairman & Consultant Pathologist

Dr. Yugam Chopra  
MD (Pathology)  
CEO & Consultant Pathologist

NAME : Baby. PRISHA  
AGE/ GENDER : 3 YRS/FEMALE  
COLLECTED BY :  
REFERRED BY : DHAMIJA HOSPITAL (AMBALA CANTT)  
BARCODE NO. : 01513520  
CLIENT CODE. : KOS DIAGNOSTIC LAB  
CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

PATIENT ID : 1555865  
REG. NO./LAB NO. : 012407200068  
REGISTRATION DATE : 20/Jul/2024 08:24 PM  
COLLECTION DATE : 20/Jul/2024 08:44PM  
REPORTING DATE : 21/Jul/2024 10:33AM

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

HAEMATOLOGY

BLEEDING TIME (BT)

BLEEDING TIME (BT) by DUKE METHOD	1 MIN 25 SEC	MINS	1 - 5
--------------------------------------	--------------	------	-------



DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra  
MD (Pathology & Microbiology)  
Chairman & Consultant Pathologist

Dr. Yugam Chopra  
MD (Pathology)  
CEO & Consultant Pathologist

NAME : Baby. PRISHA  
AGE/ GENDER : 3 YRS/FEMALE  
COLLECTED BY :  
REFERRED BY : DHAMIJA HOSPITAL (AMBALA CANTT)  
BARCODE NO. : 01513520  
CLIENT CODE. : KOS DIAGNOSTIC LAB  
CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

PATIENT ID : 1555865  
REG. NO./LAB NO. : 012407200068  
REGISTRATION DATE : 20/Jul/2024 08:24 PM  
COLLECTION DATE : 20/Jul/2024 08:44PM  
REPORTING DATE : 21/Jul/2024 10:33AM

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

CLOTTING TIME (CT)

CLOTTING TIME (CT) by CAPILLARY TUBE METHOD	4 MIN 15 SEC	MINS	4 - 9
--	--------------	------	-------



DR.VINAY CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA  
CONSULTANT PATHOLOGIST  
MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

Dr. Yugam Chopra  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Baby. PRISHA	<b>PATIENT ID</b>	: 1555865
<b>AGE/ GENDER</b>	: 3 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012407200068
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 20/Jul/2024 08:24 PM
<b>REFERRED BY</b>	: DHAMIJA HOSPITAL (AMBALA CANTT)	<b>COLLECTION DATE</b>	: 20/Jul/2024 08:44PM
<b>BARCODE NO.</b>	: 01513520	<b>REPORTING DATE</b>	: 20/Jul/2024 09:36PM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

#### PROTHROMBIN TIME STUDIES (PT/INR)

PT TEST (PATIENT) by PHOTO OPTICAL CLOT DETECTION	11.6 <sup>L</sup>	SECS	12.5 - 14.1
PT (CONTROL) by PHOTO OPTICAL CLOT DETECTION	12	SECS	
ISI by PHOTO OPTICAL CLOT DETECTION	1.1		
INTERNATIONAL NORMALISED RATIO (INR) by PHOTO OPTICAL CLOT DETECTION	0.96		0.92 - 1.14
PT INDEX by PHOTO OPTICAL CLOT DETECTION	103.45	%	

#### INTERPRETATION:-

1. INR is the parameter of choice in monitoring adequacy of oral anti-coagulant therapy. Appropriate therapeutic range varies with the disease and treatment intensity.
2. Prolonged INR suggests potential bleeding disorder /bleeding complications
3. Results should be clinically correlated.
4. Test conducted on Citrated Plasma

#### RECOMMENDED THERAPEUTIC RANGE FOR ORAL ANTI-COAGULANT THERAPY (INR)

INDICATION	INTERNATIONAL NORMALIZED RATIO (INR)
Treatment of venous thrombosis	2.0 - 3.0
Treatment of pulmonary embolism	
Prevention of systemic embolism in tissue heart valves	
Valvular heart disease	
Acute myocardial infarction	
Atrial fibrillation	
Bileaflet mechanical valve in aortic position	
Recurrent embolism	2.5 - 3.5
Mechanical heart valve	
Antiphospholipid antibodies <sup>+</sup>	

#### COMMENTS:



  
 DR. VINAY CHOPRA  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
 DR. YUGAM CHOPRA  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: <b>Baby. PRISHA</b>	<b>PATIENT ID</b>	: 1555865
<b>AGE/ GENDER</b>	: 3 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: <b>012407200068</b>
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 20/Jul/2024 08:24 PM
<b>REFERRED BY</b>	: DHAMIJA HOSPITAL (AMBALA CANTT)	<b>COLLECTION DATE</b>	: 20/Jul/2024 08:44PM
<b>BARCODE NO.</b>	: 01513520	<b>REPORTING DATE</b>	: 20/Jul/2024 09:36PM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

The prothrombin time (PT) and its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) are measures of the efficacy of the extrinsic pathway of coagulation. PT test reflects the adequacy of factors I (fibrinogen), II (prothrombin), V, VII, and X. It is used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway.

The common causes of prolonged prothrombin time are :

- 1.Oral Anticoagulant therapy.
- 2.Liver disease.
- 3.Vit K. deficiency.
- 4.Disseminated intra vascular coagulation.
- 5.Factor 5, 7 , 10 or Prothrombin deficiency





**DR.VINAY CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)



**DR.YUGAM CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS , MD (PATHOLOGY)





**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: <b>Baby. PRISHA</b>	<b>PATIENT ID</b>	: 1555865
<b>AGE/ GENDER</b>	: 3 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: <b>012407200068</b>
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 20/Jul/2024 08:24 PM
<b>REFERRED BY</b>	: DHAMIJA HOSPITAL (AMBALA CANTT)	<b>COLLECTION DATE</b>	: 20/Jul/2024 08:44PM
<b>BARCODE NO.</b>	: 01513520	<b>REPORTING DATE</b>	: 20/Jul/2024 09:30PM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

### IMMUNOPATHOLOGY/SEROLOGY

#### RHEUMATOID FACTOR (RA): QUANTITATIVE - SERUM

RHEUMATOID (RA) FACTOR QUANTITATIVE: SERUM by NEPHLOMETRY	1.68	IU/mL	NEGATIVE: < 18.0 BORDERLINE: 18.0 - 25.0 POSITIVE: > 25.0
---	------	-------	---

#### INTERPRETATION:-

##### RHEUMATOID FACTOR (RA):

1. Rheumatoid factors (RF) are antibodies that are directed against the Fc fragment of IgG altered in its tertiary structure.
2. Over 75% of patients with rheumatoid arthritis (RA) have an IgM antibody to IgG immunoglobulin. This autoantibody (RF) is diagnostically useful although it may not be etiologically related to RA.
3. Inflammatory Markers such as ESR & C-Reactive protein (CRP) are normal in about 60 % of patients with positive RA.
4. The titer of RF correlates poorly with disease activity, but those patients with high titers tend to have more severe disease course.
5. The test is useful for diagnosis and prognosis of rheumatoid arthritis.

##### RHEUMATOID ARTHRITIS:

1. Rheumatoid Arthritis is a systemic autoimmune disease that is multi-functional in origin and is characterized by chronic inflammation of the membrane lining (synovium) joints which leads to progressive joint destruction and in most cases to disability and reduction of quality life.
2. The disease spreads from small to large joints, with greatest damage in early phase.
3. The diagnosis of RA is primarily based on clinical, radiological & immunological features. The most frequent serological test is the measurement of RA factor.

##### CAUTION (FALSE POSTIVE):-

1. RA factor is not specific for Rheumatoid arthritis, as it is often present in healthy individuals with other autoimmune diseases and chronic infections.
2. Non rheumatoid and rheumatoid arthritis (RA) populations are not clearly separate with regard to the presence of rheumatoid factor (RF) (15% of RA patients have a nonreactive titer and 8% of nonrheumatoid patients have a positive titer).
3. Patients with various nonrheumatoid diseases, characterized by chronic inflammation may have positive tests for RF. These diseases include systemic lupus erythematosus, polymyositis, tuberculosis, syphilis, viral hepatitis, infectious mononucleosis, and influenza.
4. Anti-CCP have been discovered in joints of patients with RA, but not in other form of joint disease. Anti-CCP2 is HIGHLY SENSITIVE (71%) & more specific (98%) than RA factor.
5. Upto 30 % of patients with Seronegative Rheumatoid arthritis also show Anti-CCP antibodies.
6. The positive predictive value of Anti-CCP antibodies for Rheumatoid Arthritis is far greater than Rheumatoid factor.

\*\*\* End Of Report \*\*\*



*[Signature]*

**DR. VINAY CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

*[Signature]*

**DR. YUGAM CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)

